AU763041B2 - Modulation of release from dry powder formulations - Google Patents

Modulation of release from dry powder formulations Download PDF

Info

Publication number
AU763041B2
AU763041B2 AU69259/00A AU6925900A AU763041B2 AU 763041 B2 AU763041 B2 AU 763041B2 AU 69259/00 A AU69259/00 A AU 69259/00A AU 6925900 A AU6925900 A AU 6925900A AU 763041 B2 AU763041 B2 AU 763041B2
Authority
AU
Australia
Prior art keywords
particles
microns
transition temperature
phospholipids
bioactive agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU69259/00A
Other languages
English (en)
Other versions
AU6925900A (en
Inventor
Sujit K. Basu
Giovanni Caponetti
Katharina Elbert
Jeffrey S. Hrkach
Wen-I Li
Michael M. Lipp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Advanced Inhalation Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Inhalation Research Inc filed Critical Advanced Inhalation Research Inc
Publication of AU6925900A publication Critical patent/AU6925900A/en
Application granted granted Critical
Publication of AU763041B2 publication Critical patent/AU763041B2/en
Assigned to ALKERMES, INC. reassignment ALKERMES, INC. Alteration of Name(s) in Register under S187 Assignors: ADVANCED INHALATION RESEARCH, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU69259/00A 1999-08-25 2000-08-23 Modulation of release from dry powder formulations Ceased AU763041B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15074299P 1999-08-25 1999-08-25
US60/150742 1999-08-25
PCT/US2000/023048 WO2001013891A2 (en) 1999-08-25 2000-08-23 Modulation of release from dry powder formulations

Publications (2)

Publication Number Publication Date
AU6925900A AU6925900A (en) 2001-03-19
AU763041B2 true AU763041B2 (en) 2003-07-10

Family

ID=22535816

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69259/00A Ceased AU763041B2 (en) 1999-08-25 2000-08-23 Modulation of release from dry powder formulations

Country Status (6)

Country Link
US (1) US20040018243A1 (https=)
EP (1) EP1210067A2 (https=)
JP (1) JP2003507410A (https=)
AU (1) AU763041B2 (https=)
CA (1) CA2382821A1 (https=)
WO (1) WO2001013891A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7141236B2 (en) 2000-07-28 2006-11-28 Nektar Therapeutics Methods and compositions for delivering macromolecules to or via the respiratory tract
AU2002255181A1 (en) * 2001-05-21 2002-12-03 Britannia Pharmaceuticals Limited Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs
GB0120123D0 (en) * 2001-08-17 2001-10-10 Upperton Ltd Preparation of microparticles
AU2002352836B2 (en) 2001-11-20 2005-09-29 Alkermes, Inc. Improved particulate compositions for pulmonary delivery
JP2005511629A (ja) * 2001-11-20 2005-04-28 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続作用生成物送達用組成物
PT1458360E (pt) * 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
AU2003213402A1 (en) * 2002-03-18 2003-09-29 Yamanouchi Pharmaceutical Co., Ltd. Powdery medicinal compositions for inhalation and process for producing the same
WO2003079885A2 (en) 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP1569626A1 (en) 2002-12-13 2005-09-07 Adagit Pharmaceutical porous particles
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN100365039C (zh) * 2003-01-31 2008-01-30 日本瑞翁株式会社 可聚合组合物、热塑性树脂组合物、交联树脂以及交联树脂复合材料
KR20060015316A (ko) * 2003-05-28 2006-02-16 넥타르 테라퓨틱스 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
WO2006002178A1 (en) 2004-06-18 2006-01-05 Novartis Vaccines And Diagnostics Inc. Methods of treatment of endobronchial infections
WO2006124446A2 (en) * 2005-05-12 2006-11-23 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
EP1952803A1 (en) 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Solid pharmaceutical dosage form containing hydrogenated phospholipids
DE102007019186B4 (de) * 2007-04-20 2011-11-17 Qiagen Instruments Ag Pipettiergerät und Verfahren für dem Betrieb des Pipettiergerätes
CN101861311A (zh) 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
JP2011504505A (ja) 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
KR20150116466A (ko) 2009-01-26 2015-10-15 이스라엘 인스티튜트 포 바이올로지컬 리서치 이환형 헤테로사이클릭 스피로 화합물
BR112013007304B1 (pt) * 2010-09-29 2021-12-14 Pulmatrix, Inc. Pós secos de cátion de metal monovalente para inalação
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
ES2675720T3 (es) 2013-01-10 2018-07-12 Pulmokine, Inc. Inhibidores de quinasa no selectivos
US9925184B2 (en) * 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
CN106061487A (zh) * 2014-02-03 2016-10-26 里兰斯坦福初级大学理事会 用于微粒递送锌原卟啉的制剂
MX392636B (es) 2014-10-31 2025-03-24 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
AU2017281931B2 (en) * 2016-06-24 2023-02-02 Merz Pharmaceuticals, Llc Surfactant formulations for inhalation
CA3041679A1 (en) 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension
CA3085944A1 (en) * 2017-12-21 2019-06-27 Civitas Therapeutics, Inc. Surfactant formulations for inhalation
WO2019126283A1 (en) * 2017-12-21 2019-06-27 Civitas Therapeutics, Inc. Surfactant formulations for inhalation
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
EP3846792A4 (en) 2018-09-06 2022-10-12 Innopharmascreen Inc. METHODS AND COMPOSITIONS FOR TREATING ASTHMA OR PARKINSON'S DISEASE
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999016419A1 (en) * 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Perforated microparticles and methods of use

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2470296A (en) * 1948-04-30 1949-05-17 Abbott Lab Inhalator
US2992645A (en) * 1958-05-06 1961-07-18 Benger Lab Ltd Disperser for powders
US3957965A (en) * 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
US4173488A (en) * 1968-12-23 1979-11-06 Champion International Corporation Oil-in-water emulsions containing hydropholeic starch
GB1410588A (en) * 1971-08-10 1975-10-22 Fisons Ltd Composition
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4089800A (en) * 1975-04-04 1978-05-16 Ppg Industries, Inc. Method of preparing microcapsules
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
US4181542A (en) * 1976-10-25 1980-01-01 Nippon Gakki Seizo Kabushiki Kaisha Method of manufacturing junction field effect transistors
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4743545A (en) * 1984-08-09 1988-05-10 Torobin Leonard B Hollow porous microspheres containing biocatalyst
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
DE3274065D1 (de) * 1981-07-08 1986-12-11 Draco Ab Powder inhalator
EP0072046B1 (en) * 1981-07-24 1986-01-15 FISONS plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
DE3141641A1 (de) * 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4865789A (en) * 1983-11-14 1989-09-12 Akzo Nv Method for making porous structures
EP0163696B1 (en) * 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Use of a bioadhesive
US4679555A (en) * 1984-08-07 1987-07-14 Key Pharmaceuticals, Inc. Method and apparatus for intrapulmonary delivery of heparin
US5340587A (en) * 1985-05-22 1994-08-23 Liposome Technology, Inc. Liposome/bronchodilator method & System
JPS63500175A (ja) * 1985-05-22 1988-01-21 リポソ−ム　テクノロジ−，インコ−ポレイテツド リポソ−ム吸入法および吸入システム
WO1987003197A1 (en) * 1985-11-29 1987-06-04 Fisons Plc Pharmaceutical composition including sodium cromoglycate
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4990291A (en) * 1986-04-15 1991-02-05 The United States Of America As Represented By The Secretary Of The Navy Method of making lipid tubules by a cooling process
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
NZ221411A (en) * 1986-08-11 1989-10-27 Innovata Biomed Ltd Pharmaceutical compositions containing microcapsules and a surfactant
DE3637926C1 (de) * 1986-11-05 1987-11-26 Schering Ag Ultraschall-Manometrieverfahren in einer Fluessigkeit mittels Mikroblaeschen
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US4963297A (en) * 1987-12-22 1990-10-16 The Liposome Company, Inc. Spontaneous vesticulation of multilamellar liposomes
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US4855144A (en) * 1987-10-23 1989-08-08 Advanced Polymer Systems Synthetic melanin aggregates
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5064650A (en) * 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US4917119A (en) * 1988-11-30 1990-04-17 R. J. Reynolds Tobacco Company Drug delivery article
US5015483A (en) * 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
IT1228459B (it) * 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
DK0471036T4 (da) * 1989-05-04 2004-07-19 Southern Res Inst Indkapslingsfremgangsmåde
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
IT1237118B (it) * 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5123414A (en) * 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
SE9002017D0 (sv) * 1990-06-06 1990-06-06 Kabivitrum Ab Process for manufacture of matrices
US5614216A (en) * 1990-10-17 1997-03-25 The Liposome Company, Inc. Synthetic lung surfactant
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US5327883A (en) * 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP0679088B1 (en) * 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US5698721A (en) * 1992-12-17 1997-12-16 Megabios Corporation Catonic amphiphiles
US5994314A (en) * 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
PT721331E (pt) * 1993-10-01 2002-05-31 Astrazeneca Ab Processo i
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
EP0750910A4 (en) * 1994-03-11 1997-07-09 Yoshitomi Pharmaceutical PREPARATION OF LIPOSOMES
MX9605717A (es) * 1994-05-18 1998-05-31 Inhale Therapeutic Syst Metodos y composiciones para la formulacion de polvo seco de interferones.
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
AR002009A1 (es) * 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
ATE287703T1 (de) * 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6103270A (en) * 1996-06-07 2000-08-15 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
AU5719798A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
JP4549529B2 (ja) * 1998-01-30 2010-09-22 サイオス，インコーポレーテッド ペプチドまたはタンパク質の制御放出送達
EA003328B1 (ru) * 1998-04-08 2003-04-24 Эли Лилли Энд Компани Легочная и назальная доставка ралоксифена
WO1999066903A2 (en) * 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
CA2341624C (en) * 1998-08-25 2008-12-02 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999016419A1 (en) * 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Perforated microparticles and methods of use

Also Published As

Publication number Publication date
US20040018243A1 (en) 2004-01-29
AU6925900A (en) 2001-03-19
CA2382821A1 (en) 2001-03-01
JP2003507410A (ja) 2003-02-25
WO2001013891A3 (en) 2001-07-26
EP1210067A2 (en) 2002-06-05
WO2001013891A2 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
AU763041B2 (en) Modulation of release from dry powder formulations
AU2002242253B2 (en) Modulation of release from dry powder formulations
AU2002242253A1 (en) Modulation of release from dry powder formulations
CA2433335C (en) Particles for inhalation having sustained release properties
AU764738B2 (en) Use of simple amino acids to form porous particles
EP1379219B1 (en) Large, porous particles produced by controlling humidity during a spray draying process
CA2478974C (en) Inhalable sustained therapeutic formulations
US20030232019A1 (en) Inhalable formulations for sustained release
AU768299B2 (en) Formulation for spray-drying large porous particles
AU2002230993A1 (en) Particles for inhalation having sustained release properties
US7754242B2 (en) Inhalable sustained therapeutic formulations
US7252840B1 (en) Use of simple amino acids to form porous particles
US20220133708A1 (en) Inhalable sustained therapeutic formulations
AU2006220411B2 (en) Inhalable Sustained Therapeutic Formulations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)